| |
| |
SPOT ON
|
 |
MSD: dangers of rofecoxib concealed for years
|
| |
| |
THERAPIES FROM A CRITICAL VIEW POINT
|
| |
Clopidogrel (ISCOVER, PLAVIX): how long after angioplasty?
Slow-release nifedipine for angina pectoris?
|
| |
| |
NEW ON THE MARKET
|
| |
Labelling of new drugs in the a-t
Duloxetine (YENTREVE) for urinary stress incontinence
|
| |
| |
REVIEW
|
| |
How far is influenza vaccination evidence-based? |
| |
| |
a-t READERS' QUESTIONS AND COMMENTS
|
| |
Is WICK ERSTE ABWEHR effective?
Insulin glargine (LANTUS): worsening of retinopathies?
|
| |
| |
IN BRIEF
|
| |
USA: No licence for Ximelagatran (EXANTA)
Glucocorticoids increase mortality in severe head injury
Lactobacillus does not prevent post-antibiotic vulvovaginal candidiasis
Once again: quality problems of drugs used in traditional Chinese medicine (TCM)
|
| |
| |
CURRENT ADR NETWORK REPORT
|
| |
Hair loss after hexavalent vaccine (HEXAVAC)
Addendum: double reporting of a tolperisone-induced drug reaction (MYDOCALM)
|
| |
| |
SIDE EFFECTS
|
| |
Cox-2-inhibitors and cardiovascular toxicity
|
| |
| |
DOCUMENTATION
|
| |
Rise and fall of rofecoxib (VIOXX)
|
| |